Structural Formula (Figure 1 Structure)
Oxybutynin Chloride Tablet
Product Images NDC 50090-4622
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxybutynin Chloride (NDC 50090-4622). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Table 1 (Figure 2 Table1)
This appears to be a table showing some pharmacokinetic parameters for two forms of Butynin (R-Oybutynin and S-Ouybutynin). The text reports values for G (possibly concentration in ng/ml), Toa and AUC (both possibly different measures of exposure), and UGy (which could be related to clearance of the drug). However, the inconsistent format and lack of additional information makes it difficult to provide a more detailed interpretation.*
Figure 1 (Figure 3 Figure1)
Table 2 (Figure 4 Table2)
Figure 2 (Figure 5 Figure2)
Table 3 (Figure 6 Table3)
This is a report on the adverse effects of Oxybutynin Chioride. The drug is associated with several side effects across various body systems such as infections and infestations, psychiatric disorders, nervous system disorders, eye disorders, gastrointestinal disorders, and renal and urinary disorders. These include urinary tract infections, insomnia, nervousness, dizziness, somnolence, blurred vision, dry mouth, constipation, nausea, dyspepsia, urinary hesitation, and urinary retention. Some of the side effects are reported to be as high as 714%.*
Kvk Logo (Figure 7 Company Logo)
Label Image (Lbl500904622)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
